Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
15:16:19 EDT Fri 26 Apr 2024
Enter Symbol
or Name
USA
CA



Q:INM - INMED PHARMACEUTICALS INC - https://www.inmedpharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
INM - Q0.10.23·0.23930.10.238-0.015-5.9433.4814860.245  0.2484  0.22752.08  0.26214:51:17Apr 1815 min RT 2¢

Recent Trades - Last 10 of 486
Time ETExPriceChangeVolume
14:51:17Q0.238-0.015400
14:45:35Q0.2331-0.01892
14:38:26Q0.239-0.014368
14:33:21Q0.231-0.0217
14:27:18Q0.233-0.02300
14:27:18Q0.233-0.02300
14:27:18Q0.233-0.02100
14:27:18Q0.231-0.02210,890
14:20:18Q0.2393-0.012716
14:17:11Q0.2396-0.0134250

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-18 08:01U:INMNews ReleaseInMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board
2024-04-16 08:02U:INMNews ReleaseInMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration
2024-04-04 08:01U:INMNews ReleaseInMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies
2024-03-20 08:32U:INMNews ReleaseInMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance
2024-02-13 18:10U:INMSEDAR Interim Financial StatementsSEDAR Interim MD & A
2024-02-13 17:42U:INMNews ReleaseInMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update
2024-02-09 08:01U:INMNews ReleaseInMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer
2024-01-18 16:42U:INMNews ReleaseInMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET
2024-01-16 08:02U:INMNews ReleaseInMed Pharmaceuticals Provides Business Update and Milestones for 2024
2023-12-19 18:04U:INMNews ReleaseInMed Announces Results of 2023 Annual General Meeting
2023-11-29 08:01U:INMNews ReleaseInMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration
2023-11-14 08:40U:INMSEDAR Interim MD & ASEDAR Interim Financial Statements
2023-11-14 08:06U:INMNews ReleaseInMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update
2023-11-02 08:01U:INMNews ReleaseInMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023
2023-10-26 19:16U:INMNews ReleaseInMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules
2023-10-24 16:39U:INMNews ReleaseInMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules
2023-10-24 07:31U:INMNews ReleaseInMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies
2023-09-29 13:22U:INMNews ReleaseInMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update
2023-09-29 13:15U:INMSEDAR Annual ReportSEDAR Annual Report
2023-09-29 13:10U:INMSEDAR Audited Annual Financial StatementsSEDAR Audited Annual Financial Statements